Somatic Mosaicism in a Patient with Gaucher Disease Type 2: Implication for Genetic Counseling and Therapeutic Decision-Making

2000 ◽  
Vol 26 (6) ◽  
pp. 611-612 ◽  
Author(s):  
Mirella Filocamo ◽  
Gloria Bonuccelli ◽  
Raffaella Mazzotti ◽  
Fabio Corsolini ◽  
Marina Stroppiano ◽  
...  
Keyword(s):  
Decision Making ◽  
Genetic Counseling ◽  
Gaucher Disease ◽  
Somatic Mosaicism ◽  
Disease Type ◽  
Therapeutic Decision ◽  
Therapeutic Decision Making

Genotyping might help therapeutic decision-making in patients with von Willebrand disease type 2 B

Haemophilia ◽  
2016 ◽  
Vol 22 (5) ◽  
pp. e439-e443 ◽  
Author(s):  
L. Rugeri ◽  
M. Fretigny ◽  
Y. Dargaud ◽  
C. Nougier ◽  
C. Vinciguerra
Keyword(s):  
Decision Making ◽  
Disease Type ◽  
Von Willebrand Disease ◽  
Therapeutic Decision ◽  
Therapeutic Decision Making ◽  
Von Willebrand

scholarly journals Beta-cell Insufficiency

2017 ◽  
Vol 13 (02) ◽  
pp. 51 ◽  
Author(s):  
Sanjay Kalra ◽  
Yashdeep Gupta ◽  
◽  
Keyword(s):  
Type 2 Diabetes ◽  
Decision Making ◽  
Beta Cell ◽  
Taxonomic Structure ◽  
Therapeutic Decision ◽  
Anatomy And Physiology ◽  
Beta Cell Failure ◽  
Three Phase ◽  
Therapeutic Decision Making

‘B eta-cell failure’ is a frequently used term to describe the structural and functional inability of the cells to fulfil their metabolic responsibility. This editorial reviews the anatomy and physiology of the beta cell, and describes factors which regulate this. The authors focus on semantics, comparing the phrases ‘beta-cell failure’, ‘functional mass’, and ‘beta-cell insufficiency’. They suggest the use of ‘beta-cell insufficiency’, with descriptors such as ‘partial’ and ‘complete’, or ‘reversible’ and ‘irreversible’, to convey betacell dysfunction in type 2 diabetes. A three-phase taxonomic structure: beta-cell sufficiency, partial/reversible beta-cell insufficiency and complete/irreversible beta-cell insufficiency, is proposed as a tool to understand pathophysiology and facilitate therapeutic decision-making.

The Prescription as Final Common Pathway

1995 ◽  
Vol 11 (3) ◽  
pp. 384-390 ◽  
Author(s):  
Jerry Avorn
Keyword(s):  
Decision Making ◽  
Cost Effectiveness ◽  
Health Economics ◽  
Medical Care ◽  
Clinical Medicine ◽  
Decision Science ◽  
Therapeutic Decision ◽  
Common Pathway ◽  
Final Common Pathway ◽  
Therapeutic Decision Making

AbstractThere is an informational void about Pharmaceuticals in the training of most doctors, despite the importance of the prescription in medical care. The writing of the prescription is the final common pathway in therapeutic decision making, which involves such diverse forces and disciplines as anthropology, decision science, health economics, ethics, and politics, as well as pharmacology and clinical medicine. Programs to improve the precision and cost-effectiveness of doctors' prescribing must consider all of these factors if pharmacotherapeutics are to be used optimally.

Therapeutic decision making in BMT/SCT for hemoglobinopathies

2013 ◽  
pp. 179-191
Author(s):  
Shalini Shenoy ◽  
Reinhold Munker ◽  
Kerry Atkinson
Keyword(s):  
Decision Making ◽  
Therapeutic Decision ◽  
Therapeutic Decision Making

Therapeutic decision making in BMT/SCT for soft tissue sarcomas

2013 ◽  
pp. 159-164
Author(s):  
Reinhold Munker ◽  
Vishwas Sakhalkar ◽  
Hillard M. Lazarus ◽  
Kerry Atkinson
Keyword(s):  
Decision Making ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Therapeutic Decision ◽  
Therapeutic Decision Making
Sign in / Sign up

Export Citation Format

Share Document